search
Back to results

Assessment of Drug Efficacy of Local Albendazole

Primary Purpose

Helminthiasis

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
albendazole BENDEX
albendazole OVIS
Sponsored by
University Ghent
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Helminthiasis

Eligibility Criteria

5 Years - 18 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Age: 5-18 years old.
  2. Sex: males and females.
  3. Signed of written informed consent sheet by parents/or guardians, and those who volunteered to comply with study procedures (stool submission, drug treatment).
  4. Females: was not pregnant (as verbally assessed by clinician upon enrolled to treatment).

Exclusion Criteria:

  1. Had vomit within 4 hours after drug administration.
  2. Had diarrhea at time of the first sampling.
  3. Subjects who were unable to provide a stool sample at follow-up,
  4. Subjects who experienced a severe concurrent medical condition
  5. Subjects with known history of allergic reaction to ALB.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    ALB-BENDEX

    ALB-OVIS

    Arm Description

    albendazole, 400 mg, single oral dose, (BENDEX)

    albendazole, 400 mg, single-oral dose, (OVIS)

    Outcomes

    Primary Outcome Measures

    Egg reduction rate

    Secondary Outcome Measures

    Full Information

    First Posted
    March 26, 2015
    Last Updated
    December 6, 2022
    Sponsor
    University Ghent
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02420574
    Brief Title
    Assessment of Drug Efficacy of Local Albendazole
    Official Title
    Assessment of Drug Efficacy of Albendazole Bought on Local Market Against Soil-transmitted Helminth Infections in School Children in Jimma, Ethiopia
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2022
    Overall Recruitment Status
    Completed
    Study Start Date
    February 2014 (undefined)
    Primary Completion Date
    April 2014 (Actual)
    Study Completion Date
    February 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University Ghent

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Infections with soil-transmitted helminthes (STH) occur throughout the developing world and remain a major public health problem in the poorest communities. Preventive chemotherapy (PC) programs in which single-dose albendazole 400 mg or single-dose mebendazole 500 mg - the drugs of choice for STH - are administered at the population level, is the main strategy for STH control. To ensure quality, these drugs are being widely donated by GlaxoSmithKline (GSK) (albendazole (ALB), Zentel) and Johnson & Johnson (mebendazole (MEB), Vermox). In addition to this, there are a wide variety of ALB and MEB tablets available on the local market. Although little is known about the quality of anthelmintics sold for human use, several publications have reported variability in the quality of generic anthelmintics used in veterinary medicine. The main objective of the present study is to compare the efficacy of two ALB brands bought on the local market, including OVIS (Korea, DAEHWA pharmaceutical) and BENDEX (India, Cipla)
    Detailed Description
    Background Infections with soil-transmitted helminthes (STH) occur throughout the developing world and remain a major public health problem in the poorest communities. Infection is caused by four main species of worms commonly known as roundworms (Ascaris lumbricoides), whipworms (Trichuris trichiura) and hookworms (Ancylostoma duodenale and Necator americanus). It is estimated that STH affects more than 2 billion people worldwide, of which 450 million have significant morbidity attributable to their infection, and hence are one of the most important neglected tropical diseases. Children and pregnant women are the two most vulnerable groups. Children experience growth stunting and diminished physical fitness as well as impaired memory and cognition, resulting in impaired childhood educational performance and reduce school attendance; pregnant women suffer significant morbidity with hookworm-associated anemia likely contributing to maternal mortality. Preventive chemotherapy (PC) programs in which single-dose albendazole 400 mg or single-dose mebendazole 500 mg - the drugs of choice for STH - are administered at the population level, is the main strategy for STH control. To ensure quality, these drugs are being widely donated by GlaxoSmithKline (GSK) (albendazole (ALB), Zentel) and Johnson & Johnson (mebendazole (MEB), Vermox). In addition to this, there are a wide variety of ALB and MEB tablets available on the local market. Although little is known about the quality of anthelmintics sold for human use, several publications have reported variability in the quality of generic anthelmintics used in veterinary medicine. The concentrations of nine anthelmintic products (levamisol and MEB) purchased in pharmacies and from agricultural merchants in Kenya varied from 0 to 118 % of their claimed composition. Efficacy studies of seven brands of ALB against gastrointestinal nematodes in sheep in Ethiopia showed that the efficacy of only five of the seven brands was satisfactory. Objectives The main objective of the present study is to compare the efficacy of two ALB brands bought on the local market, including OVIS (Korea, DAEHWA pharmaceutical) and BENDEX (India, Cipla) Materials and methods 3.1. Study Population School children between 4 and 18 years old are the focus of this study because of two main reasons: school children are normally a major target for regular treatment with anthelminthic, because they are the group that usually has the heaviest worm burdens for A. lumbricoides and T. trichiura, and are steadily acquiring hookworm infections. In addition, they are in a period of intense physical and intellectual growth. Deworming schoolchildren has a considerable benefit on their nutritional status, physical fitness, appetite, growth and intellectual development. 3.2. Study design The study design is based on the recent WHO guidelines on how to assess drug efficacy against STH. Briefly, following obtaining informed consent, school children in the target age range group will be recruited and asked to provide a recent stool sample (an interval of less than 4 hours) that will be processed to determine the fecal egg counts (FEC) for each STH present. For the initial sampling the aim is to enroll at least 650 children. This is based on a sample size of at least 50 infected subjects for each STH in each treatment arm (cfr WHO guidelines), an apparent prevalence of 20% for the least prevalent STH species and a drop out of 20%. All children providing stool samples will be randomized across two treatment arms. Fourteen days after treatment a second fecal sample will be collected from the children to determine again FEC. Subjects who are unable to provide a stool sample at follow-up, or who are experiencing a severe concurrent medical condition or have diarrhea at time of the first sampling, will be excluded from the study. At follow-up all students will receive a single oral dose ALB tablet that was donated by GSK through WHO (Zentel). 3.3. Determination of FEC of STH All fecal samples will be processed using the McMaster egg counting technique (analytic sensitivity of 50 EPG) for the detection and the enumeration of infections with A. lumbricoides, T. trichiura and hookworms. 3.4. Statistical analysis The efficacy of the brands against each of the three STH will be measured by reduction in FEC using the formula below. The efficacy of the drugs will be classified into 'satisfactory', 'doubtful' and 'reduced' using the criteria summarized in Table 1. Table 1. The criteria based on FECR classifying efficacy of drugs into 'satisfactory', 'doubtful' and 'reduced' A. lumbricoides T. trichiura Hookworm Satisfactory FECR ≥ 95% FECR ≥ 50% FECR ≥ 90% Doubtful 95%> FECR ≥95% 50%> FECR ≥40% 90%> FECR ≥80% Reduced FECR ≤85% FECR ≤40% FECR ≤80% 3.5. Interpretation In any case of doubtful or reduced efficacy further steps will be taken to assess the efficacy of the drug. Ethical issues This study will be reviewed by the Ethics committees of the Faculty of Medicine, Ghent University (Belgium) and the Jimma University, Jimma (Ethiopia).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Helminthiasis

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    679 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    ALB-BENDEX
    Arm Type
    Active Comparator
    Arm Description
    albendazole, 400 mg, single oral dose, (BENDEX)
    Arm Title
    ALB-OVIS
    Arm Type
    Active Comparator
    Arm Description
    albendazole, 400 mg, single-oral dose, (OVIS)
    Intervention Type
    Drug
    Intervention Name(s)
    albendazole BENDEX
    Other Intervention Name(s)
    BENDEX/OVIS
    Intervention Description
    randomized clinical trial with 2 parallel arms
    Intervention Type
    Drug
    Intervention Name(s)
    albendazole OVIS
    Primary Outcome Measure Information:
    Title
    Egg reduction rate
    Time Frame
    14 days after administration of the drugs

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    5 Years
    Maximum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Age: 5-18 years old. Sex: males and females. Signed of written informed consent sheet by parents/or guardians, and those who volunteered to comply with study procedures (stool submission, drug treatment). Females: was not pregnant (as verbally assessed by clinician upon enrolled to treatment). Exclusion Criteria: Had vomit within 4 hours after drug administration. Had diarrhea at time of the first sampling. Subjects who were unable to provide a stool sample at follow-up, Subjects who experienced a severe concurrent medical condition Subjects with known history of allergic reaction to ALB.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jozef Vercruysse, PhD
    Organizational Affiliation
    University Ghent
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    16679166
    Citation
    Bethony J, Brooker S, Albonico M, Geiger SM, Loukas A, Diemert D, Hotez PJ. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet. 2006 May 6;367(9521):1521-32. doi: 10.1016/S0140-6736(06)68653-4.
    Results Reference
    background
    PubMed Identifier
    1462652
    Citation
    Bundy DA, Hall A, Medley GF, Savioli L. Evaluating measures to control intestinal parasitic infections. World Health Stat Q. 1992;45(2-3):168-79.
    Results Reference
    background
    PubMed Identifier
    12055337
    Citation
    Crompton DW, Nesheim MC. Nutritional impact of intestinal helminthiasis during the human life cycle. Annu Rev Nutr. 2002;22:35-59. doi: 10.1146/annurev.nutr.22.120501.134539. Epub 2002 Jan 4.
    Results Reference
    background
    PubMed Identifier
    8606439
    Citation
    Curtale F, Pokhrel RP, Tilden RL, Higashi G. Intestinal helminths and xerophthalmia in Nepal. A case-control study. J Trop Pediatr. 1995 Dec;41(6):334-7. doi: 10.1093/tropej/41.6.334.
    Results Reference
    background
    PubMed Identifier
    9242313
    Citation
    De Clercq D, Sacko M, Behnke J, Gilbert F, Dorny P, Vercruysse J. Failure of mebendazole in treatment of human hookworm infections in the southern region of Mali. Am J Trop Med Hyg. 1997 Jul;57(1):25-30. doi: 10.4269/ajtmh.1997.57.25.
    Results Reference
    background
    PubMed Identifier
    9586132
    Citation
    Monteiro AM, Wanyangu SW, Kariuki DP, Bain R, Jackson F, McKellar QA. Pharmaceutical quality of anthelmintics sold in Kenya. Vet Rec. 1998 Apr 11;142(15):396-8. doi: 10.1136/vr.142.15.396.
    Results Reference
    background
    PubMed Identifier
    15275558
    Citation
    Nokes C, Bundy DA. Does helminth infection affect mental processing and educational achievement? Parasitol Today. 1994 Jan;10(1):14-8. doi: 10.1016/0169-4758(94)90348-4.
    Results Reference
    background
    PubMed Identifier
    8505663
    Citation
    Stephenson LS, Latham MC, Adams EJ, Kinoti SN, Pertet A. Physical fitness, growth and appetite of Kenyan school boys with hookworm, Trichuris trichiura and Ascaris lumbricoides infections are improved four months after a single dose of albendazole. J Nutr. 1993 Jun;123(6):1036-46. doi: 10.1093/jn/123.6.1036.
    Results Reference
    background
    PubMed Identifier
    8916795
    Citation
    Stoltzfus RJ, Albonico M, Chwaya HM, Savioli L, Tielsch J, Schulze K, Yip R. Hemoquant determination of hookworm-related blood loss and its role in iron deficiency in African children. Am J Trop Med Hyg. 1996 Oct;55(4):399-404. doi: 10.4269/ajtmh.1996.55.399.
    Results Reference
    background
    PubMed Identifier
    21468309
    Citation
    Vercruysse J, Behnke JM, Albonico M, Ame SM, Angebault C, Bethony JM, Engels D, Guillard B, Nguyen TV, Kang G, Kattula D, Kotze AC, McCarthy JS, Mekonnen Z, Montresor A, Periago MV, Sumo L, Tchuente LA, Dang TC, Zeynudin A, Levecke B. Assessment of the anthelmintic efficacy of albendazole in school children in seven countries where soil-transmitted helminths are endemic. PLoS Negl Trop Dis. 2011 Mar 29;5(3):e948. doi: 10.1371/journal.pntd.0000948.
    Results Reference
    background
    Links:
    URL
    http://whqlibdoc.who.int/hq/2005/who_cds_cpe_pvc_2005.14.pdf
    Description
    World Health Organization (2005) Deworming for health and development. Report of the third global meeting of the partners for parasitic control. WHO/CDS/CPE/PVC/2005.14, World Health Organization, Geneva.
    URL
    http://medwelljournals.com/abstract/?doi=javaa.2010.2905.2911
    Description
    6. Kumsa, B., Debela, E., Megersa, B., 2010. Comparative efficacy of albendazole, tetramisole and ivermectin against gastrointestinal nematodes in naturally infected goats in Ziway, Oromia Regional State (Southern Ethiopia). J Anim Vet Adv 9, 2905-2911.

    Learn more about this trial

    Assessment of Drug Efficacy of Local Albendazole

    We'll reach out to this number within 24 hrs